NEW YORK (GenomeWeb) – Bioinformatics firm Repositive announced today that it has closed a Series A round of financing worth £2.5 million ($3.1 million).
Participants in the round included Ananda Social Venture Fund and Force Over Mass Capital, as well as existing investors Amadeus Capital Partners and Jonathan Milner. The company, which announced £500,000 in seed funding in early 2016, said it has raised £3.3 million to date.
"This investment will allow Repositive to expand its commercial offering through the development of premium features for our fast growing community of platform users worldwide," Repositive CEO Fiona Nielsen said in a statement. "Alongside this, we will invest further in expanding the range of data sources on our platform and developing further commercial products and services for the genomics R&D industry."
During 2016, Repositive launched its online portal for accessing human genomic research data and kicked off a partnership with AstraZeneca to build a pre-competitive resource — called the Repositive PDX Consortium — to provide collaborators in the pharmaceutical and drug discovery industries with access to patient-derived xenographs and associated molecular data for use in oncology research. Other members include Boehringer Ingelheim, Merck Group, Xentech, Xenopat, and Horizon Discovery.